26 May 2023
A study published in Cell Metabolism has suggested that the commonly used medicine for type 2 diabetes, canagliflozin, may be repurposed to treat T-cell driven autoimmunity as the medicine reduces T-cell activation. The scientists hope to move the study to clinical trials.
Endocrine-disrupting chemical levels found at alarming levels in Australia
11 Apr 2024
Risk of depression during menopause transition not universal
11 Apr 2024
Patients with long Covid continue to show inflammatory proteins in blood
11 Apr 2024
People with obesity and high weight linked to feeling increased pain intensity
11 Apr 2024